About Varithena: A Versatile Treatment for Your Toolkit
Varithena delivers effective treatment for a range of varicose vein anatomies and diameters, making it an option for many of your patients. The proven, effective formulation provides reliable results while reducing the risk of complications.
Treat More Varicose Veins
GSV above and below the knee, tortuosity, recanalization, large and small veins C2-C6.1 Treat them all with Vartihena.Varithena goes where thermal can’t and enhances results where thermal can.2 With Varithena, you can reach veins that a catheter can’t reach. The specialty low-nitrogen formulation is designed for reliable results over a wide range of diameters, including large veins greater than 12 mm and recurrent veins that might not be treatable with other modalities.
Treat More Patients
Varithena has been shown to be effective, even when other treatments have failed, with no exclusions based on vein diameter, vein anatomy or previous treatment. Treatments are quick, which means that you can treat more patients every day.
The Future of Venous Procedures
For many physicians, NTNT is the future of venous procedures, thanks to:
- Fewer concerns about long-term effects, infection risk and allergic reactions
- No concern about foreign bodies left behind, such as glues
- Doesn’t require incisions, wires, stripping, sedation and yields no
thermal injury risk
- It’s reimbursed: It’s now included in a majority of regional and national payers’ polices and local coverage decisions3
- Proven effective in CEAP clinical class C2 to C6 and GSV diameters from 1.5 to 25.4 mm. Varithena US [Prescribing Information]. London, UK: Provensis Ltd, a BTG International group company; Jan 2018.
- Vasquez M, et al. Phlebology. 2017;32:272-281.
- Data on file. Provensis Ltd, 2013.
- Patients reporting pain at injection or application site in clinical trials was 4.0%. BSC data on file.
Varithena® (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein (GSV) system above and below the knee. Varithena® improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.
Important Safety Information
The use of Varithena® is contraindicated in patients with known allergy to polidocanol and those with acute thromboembolic disease. Severe allergic reactions have been reported following administration of liquid polidocanol, including anaphylactic reactions, some of them fatal. Observe patients for at least 10 minutes following injection and be prepared to treat anaphylaxis appropriately. Intra-arterial injection or extravasation of polidocanol can cause severe necrosis, ischemia or gangrene. Patients with underlying arterial disease may be at increased risk for tissue ischemia. If intra-arterial injection of polidocanol occurs, consult a vascular surgeon immediately.Varithena® can cause venous thrombosis. Follow administration instructions closely and monitor for signs of venous thrombosis after treatment. Patients with reduced mobility, history of deep vein thrombosis or pulmonary embolism, or recent (within 3 months) major surgery, prolonged hospitalization, or pregnancy are at increased risk for developing thrombosis. The most common adverse events observed were pain/discomfort in extremity, retained coagulum, injection site hematoma or pain, common femoral vein thrombus extension, superficial thrombophlebitis, and deep vein thrombosis.Physicians administering Varithena® must be experienced with venous procedures, possess a detailed working knowledge of the use of the duplex ultrasound in venous disease and be trained in the administration of Varithena®.
See Full Prescribing Information for Varithena®